The new Get a Room app for Evoko Liso is more than a clever name for a meeting room management solution. As Sofie Berglund, partner relations manager and project manager for SMS/Evoko explains at ...

Liso-cel therapy significantly improves response rates and survival outcomes in relapsed/refractory CLL/SLL patients compared to standard-of-care treatments. The TRANSCEND CLL 004 trial showed a 52.5% ...

Mantle cell lymphoma is the fourth subtype of non-Hodgkin lymphoma that can be treated with this CAR T-cell therapy. Bristol Myers Squibb today announced 1 that FDA has approved lisocabtagene ...

Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, is cost-effective for second-line diffuse large B-cell lymphoma (DLBCL) therapy, according to a study published ...

Lisocabtagene maraleucel (liso-cel) shows high response rates in heavily pretreated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), with a CR/CRu rate of 60% and ORR of 83.3%.

Liso-cel achieved a 95.5% overall response rate and a 62.1% complete response rate in MZL patients after at least two prior therapies. The two-year overall survival rate for patients treated with liso ...

The study shows a significant drop in CRS and ICANS risk 15 days after liso-cel infusion, supporting reduced monitoring requirements. FDA updated guidelines now require patients to stay near ...

Please provide your email address to receive an email when new articles are posted on . Patients assigned liso-cel achieved longer median PFS and OS compared with standard of care. ORR was ...

Please provide your email address to receive an email when new articles are posted on . Second-line lisocabtagene maraleucel more than quadrupled EFS compared with standard therapy for patients with ...